Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of “Hold” by Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has earned an average recommendation of “Hold” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $70.75.

A number of equities analysts have issued reports on the company. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the transaction, the vice president directly owned 42,820 shares of the company’s stock, valued at $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently modified their holdings of the company. Amundi raised its position in shares of Prestige Consumer Healthcare by 18.1% during the first quarter. Amundi now owns 9,252 shares of the company’s stock worth $548,000 after purchasing an additional 1,421 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Prestige Consumer Healthcare by 19.4% during the first quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the company’s stock worth $91,000 after purchasing an additional 249 shares during the period. California State Teachers Retirement System raised its position in shares of Prestige Consumer Healthcare by 21.4% during the first quarter. California State Teachers Retirement System now owns 57,310 shares of the company’s stock worth $3,397,000 after purchasing an additional 10,117 shares during the period. Royal Bank of Canada raised its position in shares of Prestige Consumer Healthcare by 10.0% during the first quarter. Royal Bank of Canada now owns 57,800 shares of the company’s stock worth $3,426,000 after purchasing an additional 5,265 shares during the period. Finally, Empowered Funds LLC acquired a new position in shares of Prestige Consumer Healthcare during the first quarter worth approximately $236,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $47.65 on Friday. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of 12.19, a PEG ratio of 1.58 and a beta of 0.35. Prestige Consumer Healthcare has a 52-week low of $42.62 and a 52-week high of $85.57. The stock’s 50 day moving average price is $52.19 and its two-hundred day moving average price is $59.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The business had revenue of $281.62 million for the quarter, compared to the consensus estimate of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.Prestige Consumer Healthcare’s quarterly revenue was down 5.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities analysts predict that Prestige Consumer Healthcare will post 4.45 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).